Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg; cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg - capsule - 250 mg - active: cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide active: cefaclor monohydrate 262.3mg equivalent to cefaclor 250 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefaclor monohydrate 524.7mg equivalent to cefaclor 500 mg - capsule - 500 mg - active: cefaclor monohydrate 524.7mg equivalent to cefaclor 500 mg excipient: croscarmellose sodium dimeticone gelatin iron oxide red magnesium stearate titanium dioxide

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin - capsule - 150 mg - active: clindamycin hydrochloride 177.515mg equivalent to 150 mg clindamycin excipient: erythrosine gelatin indigo carmine lactose monohydrate magnesium stearate maize starch opacode white s-1-18086 purified talc titanium dioxide - upper respiratory infections including tonsillitis, pharyngitis, sinusitis, otitis media and scarlet fever. lower respiratory infections including bronchitis, pneumonia, empyema and lung abscess.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

multichem nz limited - iron polymaltose 50 mg/ml (318mg iron polymaltose equivalent to 100mg iron iii) - solution for injection - 50 mg/ml - active: iron polymaltose 50 mg/ml (318mg iron polymaltose equivalent to 100mg iron iii) excipient: hydrochloric acid sodium hydroxide water for injection

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

viatris limited - fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg;   - capsule - 20 mg - active: fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg   excipient: acid yellow 17 brilliant blue fcf colloidal silicon dioxide erythrosine gelatin indigo carmine lactose monohydrate magnesium stearate maize starch purified talc sodium laurilsulfate titanium dioxide   water - - depression and its associated anxiety

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

viatris limited - fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg;   - dispersible tablet - 20 mg - active: fluoxetine hydrochloride 22.36mg equivalent to fluoxetine 20 mg   excipient: colloidal silicon dioxide crospovidone magnesium stearate maize starch mentha x piperita microcrystalline cellulose saccharin sodium - in adults 18 years of age and over: - depression and its associated anxiety - bulimia nervosa - obsessive-compulsive disorder - premenstrual dysphoric disorder - a severe form of pms diagnosis of pmdd: the essential features of pmdd are clear and established cyclicity of symptom (occurring during the last week of the luteal phase in most menstrual cycles) such as depressed mood, anxiety, affective lability, and physical symptoms such as breast tenderness or swelling, headaches, joint or muscle pain, bloating, and weight gain. pmdd is a severe clinical entity and is distinguished from the broader premenstrual syndrome by the intensity of its symptoms (particularly mood symptoms) and the extent to which it interferes with social and/or occupational function.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - midazolam maleate 20.8mg equivalent to 15 mg midazolam - tablet - 15 mg - active: midazolam maleate 20.8mg equivalent to 15 mg midazolam excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - midazolam maleate 10.2mg equivalent to 7.5 mg midazolam;   - tablet - 7.5 mg - active: midazolam maleate 10.2mg equivalent to 7.5 mg midazolam   excipient: hypromellose lactose magnesium stearate microcrystalline cellulose purified talc starch titanium dioxide - short-term treatment of insomnia. benzodiazepines are only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

miro healthcare limited - amoxicillin trihydrate 287.5mg equivalent to amoxicillin 250 mg;  ;   - capsule - 250 mg - active: amoxicillin trihydrate 287.5mg equivalent to amoxicillin 250 mg     excipient: brilliant blue fcf carmoisine croscarmellose sodium gelatin ink magnesium stearate methyl hydroxybenzoate propyl hydroxybenzoate purified water quinoline yellow sodium laurilsulfate sunset yellow fcf   titanium dioxide   - amoxicillin is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: upper respiratory infections: otitis media, pharyngitis, sinusitis and tonsillitis. lower respiratory infections: bronchitis, bronchopneumonia and lobar pneumonia. urinary tract infections: cystitis, cysto-pyelitis, urethritis, and gonococcal urethritis. prophylaxis: against ?-haemolytic (viridans group) and ?-haemolytic streptococci before dental, oral or upper respiratory tract surgery or instrumentation. prophylaxis: of bacterial endocarditis in patients with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular lesions, prosthetic heart valves, previous history of bacterial endocarditis, hypertrophic cardiomyopathy, surgically constructed systemic-pulmonary shunts, mitral valve prolapse with valvular regurgitation or mitral valve prolapse without valvular regurgitation but associated with thickening and/or redundancy of the valve leaflets. amoxicillin is further indicated for the treatment of cutaneous infections. in emergency cases where the causative organism is not yet identified, therapy may be initiated with amoxicillin on the basis of clinical judgement, while awaiting the results of bacteriologic studies to determine its antimicrobial sensitivity.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

miro healthcare limited - amoxicillin trihydrate 575mg equivalent to amoxicillin 500 mg;  ;   - capsule - 500 mg - active: amoxicillin trihydrate 575mg equivalent to amoxicillin 500 mg     excipient: brilliant blue fcf carmoisine croscarmellose sodium gelatin ink magnesium stearate methyl hydroxybenzoate propyl hydroxybenzoate purified water quinoline yellow sodium laurilsulfate sunset yellow fcf   titanium dioxide   - amoxicillin is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms: upper respiratory infections: otitis media, pharyngitis, sinusitis and tonsillitis. lower respiratory infections: bronchitis, bronchopneumonia and lobar pneumonia. urinary tract infections: cystitis, cysto-pyelitis, urethritis, and gonococcal urethritis. prophylaxis: against ?-haemolytic (viridans group) and ?-haemolytic streptococci before dental, oral or upper respiratory tract surgery or instrumentation. prophylaxis: of bacterial endocarditis in patients with any of the following conditions: congenital cardiac malformations, rheumatic and other acquired valvular lesions, prosthetic heart valves, previous history of bacterial endocarditis, hypertrophic cardiomyopathy, surgically constructed systemic-pulmonary shunts, mitral valve prolapse with valvular regurgitation or mitral valve prolapse without valvular regurgitation but associated with thickening and/or redundancy of the valve leaflets. amoxicillin is further indicated for the treatment of cutaneous infections. in emergency cases where the causative organism is not yet identified, therapy may be initiated with amoxicillin on the basis of clinical judgement, while awaiting the results of bacteriologic studies to determine its antimicrobial sensitivity.